Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GEM OS1 as effective as autograft for the stimulation of bone healing

Dec. 18, 2006

Phase II data support once-daily Gabapentin GR in diabetic peripheral neuropathy

Dec. 15, 2006

MicroIslet holds pre-IND meeting for allotransplantation approach in diabetes

Dec. 15, 2006

Novel treatment options for metabolic disorders described in recent patent literature

Dec. 15, 2006

Senicapoc safe, beneficial with long-term treatment in sickle cell disease

Dec. 15, 2006

EvaMist NDA accepted for review

Dec. 14, 2006

SLV-319 begins phase IIb study for obesity

Dec. 13, 2006

V-24343 begins phase I trial for obesity and type 2 diabetes

Dec. 13, 2006

NB-S101 studied in phase II trial for osteoporosis

Dec. 13, 2006

Recent patents report new therapeutic agents for endocrine-related disorders

Dec. 12, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...